Dr. Reddy’s Schedules May 2026 Investor Conferences in Mumbai and Singapore
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
On May 11, 2026, Dr. Reddy’s Laboratories announced its upcoming participation in a series of analyst and institutional investor meetings organized by international banks. The company notified stock exchanges in India and the U.S., underscoring its engagement with global capital markets and its practice of providing structured access to senior management for investors.
Management will attend an HSBC-hosted investor conference in Mumbai from May 14 to 15, 2026, followed by a Bank of America conference in Singapore from May 18 to 19, 2026. Both events will be in-person group meetings across full business days, indicating a proactive investor-relations push that may help deepen institutional coverage and support the company’s visibility among regional and global investors, though schedules remain subject to change.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana. It develops, manufactures and markets generic and branded formulations as well as active pharmaceutical ingredients, with a significant presence in key regulated markets and listings on the NSE, BSE, NYSE and NSE IFSC.
Average Trading Volume: 2,375,381
Technical Sentiment Signal: Hold
Current Market Cap: $11.29B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
